KNTPF (Kintor Pharmaceutical) Total Operating Expense : $23.21 Mil (TTM As of Dec. 2024)

View and export this data going back to 2020. Start your Free Trial

What is Kintor Pharmaceutical Total Operating Expense?

Kintor Pharmaceutical's Total Operating Expense for the six months ended in Dec. 2024 was $12.87 Mil. Kintor Pharmaceutical's Total Operating Expense for the trailing twelve months (TTM) ended in Dec. 2024 was $23.21 Mil.

Kintor Pharmaceutical Total Operating Expense Historical Data

The historical data trend for Kintor Pharmaceutical's Total Operating Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Kintor Pharmaceutical Total Operating Expense Chart

Kintor Pharmaceutical Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Total Operating Expense

Get a 7-Day Free Trial

61.13

136.49

138.97

143.48

22.82

Kintor Pharmaceutical Semi-Annual Data
	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24	Dec24
Total Operating Expense	Get a 7-Day Free Trial								62.40	30.23	113.17	10.34	12.87

Kintor Pharmaceutical Total Operating Expense Calculation

Total Operating Expense is the primary recurring expense associated with central operations that are incurred in order to generate sales.

Total Operating Expense for the trailing twelve months (TTM) ended in Dec. 2024 adds up the semi-annually data reported by the company within the most recent 12 months, which was $23.21 Mil.

Kintor Pharmaceutical Total Operating Expense Related Terms

Thank you for viewing the detailed overview of Kintor Pharmaceutical's Total Operating Expense provided by GuruFocus.com. Please click on the following links to see related term pages.

Kintor Pharmaceutical Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Kintor Pharmaceutical Ltd (OTCPK:KNTPF) » Definitions » Total Operating Expense

Comparable Companies

Traded in Other Exchanges

09939:Hong Kong

Address

No. 20 Songbei Road, Suzhou Industrial Park, Jiangsu, Suzhou, CHN, 215123

Website

https://www.kintor.com.cn

Kintor Pharmaceutical Ltd is a clinical-stage novel drug developer in China focused on the proprietary R&D of drugs for cancers and other AR-related diseases. The company's drug candidate, Pruxelutamide, is a drug undergoing phase III clinical trials in China and phase III clinical trials in the United States for mCRPC as well as clinical trials for breast cancer. Its pipeline of seven drug candidates includes Pruxelutamide (GT0918), Pyrilutamide (KX-826), ALK-1 (GT90001), Detorsertib (GT0486), Hedgehog/SMO Inhibitor (GT1708F), PD-L1/TGF-B (GT90008), and AR-PROTAC Compound (GT20029). The company operates in a single segment focusing on the research and development of medical products.